Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
News Janssen makes EMA marketing application for talquetamab for ... The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), seeking approval of talqueta
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.